Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01577459 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01577459 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 18 participants.
The verdict
NCT01577459, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a randomized, double-blinded, placebo-controlled, crossover study to evaluate the pressor effects of pseudoephedrine when administered with TR-701 FA in healthy adult volunteers.
Interventions
- DRUG TR-701 FA with PSE
- OTHER TR-701 FA Placebo with PSE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-04-23 |
| Est. Completion | 2012-06-15 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01577459
The ClinicalTrials.gov registry entry for NCT01577459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TR-701 FA with PSE is the first listed.
NCT01577459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01577459 about?
NCT01577459 is a clinical study titled "A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response". This is a randomized, double-blinded, placebo-controlled, crossover study to evaluate the pressor effects of pseudoephedrine when administered with TR-701 FA in healthy adult volunteers.
What is the current status of trial NCT01577459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-04-23. Estimated completion is 2012-06-15.
What interventions are being tested in trial NCT01577459?
The interventions under investigation include: TR-701 FA with PSE (DRUG), TR-701 FA Placebo with PSE (OTHER).
Who is sponsoring clinical trial NCT01577459?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.